213-Bismuth-labeled antibody to gp41 glycoprotein kills ART-treated lymphocytes from HIV patients and HIV-infected monocytes in human blood brain barrier model
Eliminating virally infected cells is an essential component of HIV eradication strategy. In addition, many patients on antiretroviral therapy (ART) suffer from HIV-associated neurocognitive disorders because the brain becomes a reservoir for infection. There is a need for drugs that can enter into the CNS and eradicate the infection. Radioimmunotherapy (RIT), a clinically established method to kill cells using radiolabeled antibodies, was recently applied to target the HIV gp41 glycoprotein expressed on the surface of infected cells.
MCFARREN A;
TSUKROV D;
EUGENIN E;
LOPEZ L;
WILLIAMS D;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
ZOLLA-PAZNER S.;
GORNY M.K.;
CASADEVALL Arturo;
BERMAN J;
DADACHOVA E.;
2013-06-26
Oak Ridge National Laboratory
JRC82792
https://register.ornl.gov/2013/TATS/index.shtml,
https://publications.jrc.ec.europa.eu/repository/handle/JRC82792,
Additional supporting files
| File name | Description | File type | |
|---|
